Annual Gross Profit
$8.27 M
-$5.70 M-40.79%
31 December 2023
Summary:
Lineage Cell Therapeutics annual gross profit is currently $8.27 million, with the most recent change of -$5.70 million (-40.79%) on 31 December 2023. During the last 3 years, it has risen by +$7.89 million (+2032.47%). LCTX annual gross profit is now -40.79% below its all-time high of $13.97 million, reached on 31 December 2022.LCTX Gross Profit Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Quarterly Gross Profit
$3.74 M
+$2.38 M+174.27%
30 September 2024
Summary:
Lineage Cell Therapeutics quarterly gross profit is currently $3.74 million, with the most recent change of +$2.38 million (+174.27%) on 30 September 2024. Over the past year, it has increased by +$2.66 million (+247.35%). LCTX quarterly gross profit is now -26.08% below its all-time high of $5.06 million, reached on 31 March 2022.LCTX Quarterly Gross Profit Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
TTM Gross Profit
$8.28 M
+$2.66 M+47.41%
30 September 2024
Summary:
Lineage Cell Therapeutics TTM gross profit is currently $8.28 million, with the most recent change of +$2.66 million (+47.41%) on 30 September 2024. Over the past year, it has increased by +$28.00 thousand (+0.34%). LCTX TTM gross profit is now -40.73% below its all-time high of $13.97 million, reached on 31 December 2022.LCTX TTM Gross Profit Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
LCTX Gross Profit Performance
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | -40.8% | +247.3% | +0.3% |
| 3 y3 years | +2032.5% | +207.4% | +369.0% |
| 5 y5 years | +642.7% | +3532.0% | +1640.1% |
LCTX Gross Profit High & Low
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3 years | -40.8% | +2032.5% | -26.1% | +394.8% | -40.7% | +369.0% |
| 5 y | 5 years | -40.8% | +2032.5% | -26.1% | >+9999.0% | -40.7% | +2034.8% |
| alltime | all time | -40.8% | +1754.8% | -26.1% | +429.3% | -40.7% | +2170.8% |
Lineage Cell Therapeutics Gross Profit History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sept 2024 | - | $3.74 M(+174.3%) | $8.28 M(+47.4%) |
| June 2024 | - | $1.36 M(+1.3%) | $5.62 M(-23.6%) |
| Mar 2024 | - | $1.35 M(-26.5%) | $7.35 M(-11.1%) |
| Dec 2023 | $8.27 M(-40.8%) | $1.83 M(+70.1%) | $8.27 M(+0.2%) |
| Sept 2023 | - | $1.08 M(-65.2%) | $8.26 M(-17.0%) |
| June 2023 | - | $3.10 M(+36.7%) | $9.94 M(-11.1%) |
| Mar 2023 | - | $2.27 M(+25.0%) | $11.18 M(-20.0%) |
| Dec 2022 | $13.97 M(+465.8%) | $1.81 M(-34.4%) | $13.97 M(+8.2%) |
| Sept 2022 | - | $2.76 M(-36.3%) | $12.92 M(+13.6%) |
| June 2022 | - | $4.34 M(-14.3%) | $11.37 M(+54.7%) |
| Mar 2022 | - | $5.06 M(+569.4%) | $7.35 M(+197.6%) |
| Dec 2021 | $2.47 M(+536.6%) | $756.00 K(-37.9%) | $2.47 M(+39.9%) |
| Sept 2021 | - | $1.22 M(+285.1%) | $1.77 M(+123.8%) |
| June 2021 | - | $316.00 K(+74.6%) | $789.00 K(+58.8%) |
| Mar 2021 | - | $181.00 K(+248.1%) | $497.00 K(+28.1%) |
| Dec 2020 | $388.00 K(-63.6%) | $52.00 K(-78.3%) | $388.00 K(-62.9%) |
| Sept 2020 | - | $240.00 K(+900.0%) | $1.04 M(+15.1%) |
| June 2020 | - | $24.00 K(-66.7%) | $908.00 K(-11.6%) |
| Mar 2020 | - | $72.00 K(-89.8%) | $1.03 M(-3.7%) |
| Dec 2019 | $1.07 M(-4.3%) | $709.00 K(+588.3%) | $1.07 M(+123.9%) |
| Sept 2019 | - | $103.00 K(-28.0%) | $476.00 K(-20.9%) |
| June 2019 | - | $143.00 K(+28.8%) | $602.00 K(-37.2%) |
| Mar 2019 | - | $111.00 K(-6.7%) | $959.00 K(-13.9%) |
| Dec 2018 | $1.11 M(-31.4%) | $119.00 K(-48.0%) | $1.11 M(-26.2%) |
| Sept 2018 | - | $229.00 K(-54.2%) | $1.51 M(-10.8%) |
| June 2018 | - | $500.00 K(+88.0%) | $1.69 M(+7.9%) |
| Mar 2018 | - | $266.00 K(-48.3%) | $1.57 M(-3.4%) |
| Dec 2017 | $1.62 M(-14.3%) | $515.00 K(+25.3%) | $1.62 M(-13.9%) |
| Sept 2017 | - | $411.00 K(+9.3%) | $1.89 M(+4.4%) |
| June 2017 | - | $376.00 K(+16.8%) | $1.81 M(-1.9%) |
| Mar 2017 | - | $322.00 K(-58.6%) | $1.84 M(-2.1%) |
| Dec 2016 | $1.89 M(+32.7%) | $778.00 K(+134.3%) | $1.88 M(+24.7%) |
| Sept 2016 | - | $332.00 K(-19.2%) | $1.51 M(-4.8%) |
| June 2016 | - | $411.00 K(+13.9%) | $1.58 M(+6.7%) |
| Mar 2016 | - | $361.00 K(-10.9%) | $1.49 M(+4.2%) |
| Dec 2015 | $1.43 M(+28.6%) | $405.00 K(-0.7%) | $1.43 M(+14.7%) |
| Sept 2015 | - | $408.00 K(+30.8%) | $1.24 M(+8.4%) |
| June 2015 | - | $312.00 K(+3.7%) | $1.15 M(+9.2%) |
| Mar 2015 | - | $301.00 K(+35.6%) | $1.05 M(-5.2%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Dec 2014 | $1.11 M(-46.3%) | $222.00 K(-28.8%) | $1.11 M(-42.4%) |
| Sept 2014 | - | $312.00 K(+45.1%) | $1.92 M(-1.8%) |
| June 2014 | - | $215.00 K(-40.1%) | $1.96 M(-6.1%) |
| Mar 2014 | - | $359.10 K(-65.4%) | $2.09 M(+0.9%) |
| Dec 2013 | $2.07 M(+64.3%) | $1.04 M(+199.0%) | $2.07 M(+49.0%) |
| Sept 2013 | - | $347.00 K(+1.5%) | $1.39 M(-3.2%) |
| June 2013 | - | $342.00 K(+0.2%) | $1.43 M(+4.7%) |
| Mar 2013 | - | $341.40 K(-4.6%) | $1.37 M(+8.8%) |
| Dec 2012 | $1.26 M(-20.7%) | $357.80 K(-8.8%) | $1.26 M(-634.1%) |
| Sept 2012 | - | $392.20 K(+41.5%) | -$235.60 K(-145.7%) |
| June 2012 | - | $277.20 K(+19.9%) | $515.30 K(-48.1%) |
| Mar 2012 | - | $231.10 K(-120.3%) | $993.70 K(-37.4%) |
| Dec 2011 | $1.59 M(+18.1%) | -$1.14 M(-199.4%) | $1.59 M(-12.1%) |
| Sept 2011 | - | $1.14 M(+51.3%) | $1.81 M(+22.2%) |
| June 2011 | - | $755.60 K(-8.4%) | $1.48 M(+5.4%) |
| Mar 2011 | - | $824.60 K(-189.9%) | $1.40 M(+4.2%) |
| Dec 2010 | $1.34 M(-30.2%) | -$917.40 K(-212.5%) | $1.35 M(-55.3%) |
| Sept 2010 | - | $815.30 K(+19.8%) | $3.01 M(+13.9%) |
| June 2010 | - | $680.30 K(-11.4%) | $2.64 M(+10.4%) |
| Mar 2010 | - | $768.10 K(+2.5%) | $2.40 M(+24.5%) |
| Dec 2009 | $1.93 M(+28.0%) | $749.30 K(+67.6%) | $1.93 M(+63.7%) |
| Sept 2009 | - | $447.00 K(+3.4%) | $1.18 M(+61.3%) |
| June 2009 | - | $432.10 K(+45.6%) | $728.80 K(+145.6%) |
| Mar 2009 | - | $296.70 K(+313.2%) | $296.70 K(+110.4%) |
| Dec 2008 | $1.50 M(+1074.8%) | - | - |
| Dec 2000 | $128.00 K(-88.3%) | $71.80 K(+272.0%) | $141.00 K(+103.8%) |
| Sept 2000 | - | $19.30 K(-25.5%) | $69.20 K(+38.7%) |
| June 2000 | - | $25.90 K(+7.9%) | $49.90 K(+107.9%) |
| Mar 2000 | - | $24.00 K(-124.0%) | $24.00 K(-124.0%) |
| Dec 1999 | $1.10 M(-319.4%) | - | - |
| Sept 1995 | - | -$100.00 K(0.0%) | -$100.00 K(-75.0%) |
| Dec 1993 | - | -$100.00 K(0.0%) | -$400.00 K(0.0%) |
| Sept 1993 | - | -$100.00 K(-50.0%) | -$400.00 K(+33.3%) |
| June 1993 | -$500.00 K(+66.7%) | -$200.00 K(<-9900.0%) | -$300.00 K(0.0%) |
| Mar 1993 | - | $0.00(-100.0%) | -$300.00 K(0.0%) |
| Dec 1992 | - | -$100.00 K(<-9900.0%) | -$300.00 K(+50.0%) |
| Sept 1992 | - | $0.00(-100.0%) | -$200.00 K(0.0%) |
| June 1992 | -$300.00 K | -$200.00 K(<-9900.0%) | -$200.00 K(<-9900.0%) |
| Mar 1992 | - | $0.00 | $0.00 |
FAQ
- What is Lineage Cell Therapeutics annual gross profit?
- What is the all time high annual gross profit for Lineage Cell Therapeutics?
- What is Lineage Cell Therapeutics annual gross profit year-on-year change?
- What is Lineage Cell Therapeutics quarterly gross profit?
- What is the all time high quarterly gross profit for Lineage Cell Therapeutics?
- What is Lineage Cell Therapeutics quarterly gross profit year-on-year change?
- What is Lineage Cell Therapeutics TTM gross profit?
- What is the all time high TTM gross profit for Lineage Cell Therapeutics?
- What is Lineage Cell Therapeutics TTM gross profit year-on-year change?
What is Lineage Cell Therapeutics annual gross profit?
The current annual gross profit of LCTX is $8.27 M
What is the all time high annual gross profit for Lineage Cell Therapeutics?
Lineage Cell Therapeutics all-time high annual gross profit is $13.97 M
What is Lineage Cell Therapeutics annual gross profit year-on-year change?
Over the past year, LCTX annual gross profit has changed by -$5.70 M (-40.79%)
What is Lineage Cell Therapeutics quarterly gross profit?
The current quarterly gross profit of LCTX is $3.74 M
What is the all time high quarterly gross profit for Lineage Cell Therapeutics?
Lineage Cell Therapeutics all-time high quarterly gross profit is $5.06 M
What is Lineage Cell Therapeutics quarterly gross profit year-on-year change?
Over the past year, LCTX quarterly gross profit has changed by +$2.66 M (+247.35%)
What is Lineage Cell Therapeutics TTM gross profit?
The current TTM gross profit of LCTX is $8.28 M
What is the all time high TTM gross profit for Lineage Cell Therapeutics?
Lineage Cell Therapeutics all-time high TTM gross profit is $13.97 M
What is Lineage Cell Therapeutics TTM gross profit year-on-year change?
Over the past year, LCTX TTM gross profit has changed by +$28.00 K (+0.34%)